BR112013029647A2 - Disgnóstico de doenças de infecção respiratória usando amostras de urina - Google Patents

Disgnóstico de doenças de infecção respiratória usando amostras de urina

Info

Publication number
BR112013029647A2
BR112013029647A2 BR112013029647A BR112013029647A BR112013029647A2 BR 112013029647 A2 BR112013029647 A2 BR 112013029647A2 BR 112013029647 A BR112013029647 A BR 112013029647A BR 112013029647 A BR112013029647 A BR 112013029647A BR 112013029647 A2 BR112013029647 A2 BR 112013029647A2
Authority
BR
Brazil
Prior art keywords
respiratory infection
antibiotic
infection
diagnosis
respiratory
Prior art date
Application number
BR112013029647A
Other languages
English (en)
Other versions
BR112013029647B1 (pt
Inventor
Kamon Shirakawa
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of BR112013029647A2 publication Critical patent/BR112013029647A2/pt
Publication of BR112013029647B1 publication Critical patent/BR112013029647B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

diagnóstico de doenças de infecção respiratória usando amostras de urina. são fornecidos um método para detectar a infecção respiratória associada com uma infecção bacteriana, um método para a seleção de pacientes com infecção respiratória para receber um antibiótico, e um método para a determinação do tempo para o fim de administração do antibiótico a um paciente com infecção respiratória receber o antibiótico, em que referidos métodos são caracterizados pelo fato de serem capazes de selecionar adequadamente pacientes com infecções respiratórias às quais é o antibiótico a ser administrado, para ajustar o período de administração do antibiótico, e para tratar a infecção respiratória associada com uma infecção bacteriana, e em que um valor medido de scd14-st na urina é utilizado corno uma indicação.
BR112013029647-0A 2011-05-19 2012-05-18 Métodos para detectar a infecção respiratória associada com uma infecção bacteriana, selecionar pacientes com infecção respiratória para receber um antibiótico, determinar o tempo para o fim da administração de um antibiótico a um paciente com infecção respiratória recebendo o antibiótico, selecionar pacientes para o fim da administração de um antibiótico a partir de pacientes com infecção respiratória recebendo o antibiótico BR112013029647B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-112699 2011-05-19
JP2011112699 2011-05-19
PCT/JP2012/062797 WO2012157751A1 (ja) 2011-05-19 2012-05-18 尿検体を用いた呼吸器感染症の診断

Publications (2)

Publication Number Publication Date
BR112013029647A2 true BR112013029647A2 (pt) 2022-02-08
BR112013029647B1 BR112013029647B1 (pt) 2023-02-23

Family

ID=47177065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029647-0A BR112013029647B1 (pt) 2011-05-19 2012-05-18 Métodos para detectar a infecção respiratória associada com uma infecção bacteriana, selecionar pacientes com infecção respiratória para receber um antibiótico, determinar o tempo para o fim da administração de um antibiótico a um paciente com infecção respiratória recebendo o antibiótico, selecionar pacientes para o fim da administração de um antibiótico a partir de pacientes com infecção respiratória recebendo o antibiótico

Country Status (13)

Country Link
US (2) US9297802B2 (pt)
EP (1) EP2711710B1 (pt)
JP (1) JP5956435B2 (pt)
KR (1) KR101935072B1 (pt)
CN (1) CN103635805B (pt)
AU (1) AU2012256683B2 (pt)
BR (1) BR112013029647B1 (pt)
CA (1) CA2836565C (pt)
ES (1) ES2628868T3 (pt)
MX (1) MX352625B (pt)
RU (1) RU2664707C2 (pt)
WO (1) WO2012157751A1 (pt)
ZA (1) ZA201308675B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2723554C2 (ru) 2011-05-19 2020-06-16 Мотида Фармасьютикал Ко., Лтд. Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови
ES2623879T3 (es) * 2012-12-28 2017-07-12 Lsi Medience Corporation Uso de sCD14, sus fragmentos o sus derivados para la estratificación, diagnóstico y pronóstico del riesgo
CN113092756A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液凝血酶原及其多肽片段在过敏性疾病中的应用
JPWO2023277130A1 (pt) 2021-06-30 2023-01-05

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095411A1 (en) 2001-05-18 2002-11-28 Virogates Aps A method of diagnosing or prognosticating major respiratory bacterial pathogens in a subject
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
DE60331677D1 (de) 2002-11-12 2010-04-22 Mochida Pharm Co Ltd Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CA2566101C (en) * 2004-05-11 2013-05-21 Mochida Pharmaceutical Co., Ltd. Novel soluble cd14 antigen
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
ES2628944T3 (es) * 2008-05-23 2017-08-04 Mochida Pharmaceutical Co., Ltd. Método para la evaluación de la función de fagocitos
WO2012096245A1 (ja) * 2011-01-11 2012-07-19 三菱化学メディエンス株式会社 敗血症の予後の予測方法
RU2723554C2 (ru) 2011-05-19 2020-06-16 Мотида Фармасьютикал Ко., Лтд. Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови

Also Published As

Publication number Publication date
US9297802B2 (en) 2016-03-29
EP2711710A1 (en) 2014-03-26
JPWO2012157751A1 (ja) 2014-07-31
BR112013029647B1 (pt) 2023-02-23
KR101935072B1 (ko) 2019-01-03
RU2664707C2 (ru) 2018-08-21
AU2012256683B2 (en) 2017-02-02
ZA201308675B (en) 2015-02-25
US20160169889A1 (en) 2016-06-16
US10054585B2 (en) 2018-08-21
CN103635805B (zh) 2016-03-02
EP2711710A4 (en) 2014-12-17
KR20140033439A (ko) 2014-03-18
ES2628868T3 (es) 2017-08-04
CN103635805A (zh) 2014-03-12
CA2836565A1 (en) 2012-11-22
AU2012256683A1 (en) 2014-01-16
US20140171359A1 (en) 2014-06-19
MX352625B (es) 2017-12-01
EP2711710B1 (en) 2017-04-26
CA2836565C (en) 2021-04-27
JP5956435B2 (ja) 2016-07-27
RU2013156365A (ru) 2015-06-27
MX2013013399A (es) 2013-12-12
WO2012157751A1 (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
BRPI1100666A2 (pt) Método para produzir um l-aminoácido
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
BR112015004135A2 (pt) formas cristalinas de 1-(5'-(5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-di-hidroisoxazol-3-il)-3'h-espiro[azetidina-3,1'-isobenzofuran]-1-il)-2-(metilsulfonil)etanona
BR112013009395A2 (pt) derivados de quinazolin-4 (3h)-ona usados como inibidores da pi3 cinase
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
ECSP13013007A (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
BR112012022509A2 (pt) procalcitonina para o diagnóstico de infecções bacterianas e orientação de tratamento antibiótico em pacientes com queixas não específicas.
BR112013029647A2 (pt) Disgnóstico de doenças de infecção respiratória usando amostras de urina
BR112014003640A2 (pt) métodos para perda de peso e composições cetogênicas
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
BR112013029645A2 (pt) Diagnóstico de doença de infecção respiratória usando amostras de sangue
AR078309A1 (es) Metodo para el diagnostico de esteatohepatitis no alcoholica basado en un perfil metabolomico
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
EA201301168A1 (ru) Аклидиний для применения при улучшении качества сна у пациентов с респираторными заболеваниями
WO2014072823A3 (en) Device for blood glucose level determination
BR112013008037A2 (pt) compostos multivalentes como tratamento antibiótico
BR112012023485A2 (pt) marcadores moleculares para infecções do trato urinário.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.